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Abstract
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast
cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational
therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family
member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of
these receptors are sometimes overexpressed in breast cancer, and still subject to
regulation by hormones and other physiological regulators. Optimal use of therapeutics
targeting these receptors will require consideration of the several modes of regulation of
these receptors and their interactions with steroid receptors.
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Introduction
The close of the millenium is marked by unprecedented
advances in our understanding of the mechanisms that
underlie carcinogenesis. Each procarcinogenic pathway
presents pharmacologists with an array of therapeutic
targets. Most importantly, the first rational therapeutic
agents targeted at oncogene products have now navi-
gated the tortuous drug development pipeline. A mono-
clonal antibody, ‘Herceptin’, which binds to the receptor
tyrosine kinase (RTK) Her-2/Neu/ErbB-2 is effective for
treatment of a subset of patients with advanced breast
cancer [1••,2••]. This antibody is at the vanguard of a host
of therapeutic compounds that are under development to
antagonize the activities of ErbB family receptors.
The development and application of clinical tools that inter-
vene in ErbB-regulated processes will be most effective if
close attention is paid to the biologic properties of these
RTKs. Signaling through these receptors, even when they
are overexpressed in tumors, is still subject to regulation.
This means that there are potentially many points of vulnera-
bility at which therapeutic interventions can be targeted. Fur-
thermore, the ability of overexpressed ErbB family RTKs to
alter responses to genotoxic drugs and to steroid hormones
means that ErbB-targeted therapies will have complex inter-
actions with existing breast cancer therapeutic agents.
Amplification of ErbB family receptors
The ERBB family consists of four closely related genes:
ERBB (HER), ERBB-2 (HER-2, NEU), ERBB-3 (HER-3),
and ERBB-4 (HER-4). ERBB (HER) encodes the proto-
type EGF receptor, and the other genes encode struc-
turally similar RTKs. ERBB-2 is amplified (extensively
reduplicated) in 15–30% of breast cancers [3••]. Amplifi-
cation is more common in tumors from patients with lymph
node metastases than in those from node-negative
patients (for review [4•]). Amplification and/or overexpres-
sion of ErbB-2 occurs most often (up to 60%) in in situ
carcinomas [4•,5], so ErbB-2 overexpression may be an
early change. ErbB-2 overexpression in conjunction with
amplification, and in another few percent of breast
cancers without gene amplification, is further accentuatedhttp://breast-cancer-research.com/content/2/3/176
by transcriptional upregulation of ERBB2, which is medi-
ated by the transcription factor AP-2 [6].
The finding that a particular tumor type is associated with
amplification of a particular gene suggests that the amplifi-
cation incurs a selective advantage for the tumor. Ampli-
cons may affect more than one gene, but ERBB2 is a
common element in 17q21 amplification. Overexpression
of coamplified genes, including GRB7, may also con-
tribute to selection for this genetic change [7,8].
EGF family receptors normally function in regulation of
mammary growth and differentiation. Overexpression of
ErbB-2 in tissue culture or in transgenic mouse mammary
glands leads to transformation, tumorigenicity, and metas-
tasis, which is unusual for RTKs that are overexpressed in
the absence of ligands [9•,10]. These findings implicate
ErbB-2 as a major player in initiation and/or progression of
breast cancer. This conclusion has now been substanti-
ated with the demonstrated efficacy of ErbB-2-targeted
therapeutic antibodies.
Other ErbB family receptors apart from ErbB-2 are ampli-
fied or overexpressed in breast cancer. Amplification and
overexpression of the EGF receptor is well documented,
but there is a wide range in the reported frequencies of
EGF receptor overexpression [3••,11•]. Overexpression of
ERBB3 has been reported in breast cancer [12,13••,14].
Thus, EGF receptor, ErbB-2, and ErbB-3 are positively
regulated in breast cancer. In contrast, overexpression of
ErbB-4 is uncommon in breast cancer, and ErbB4 expres-
sion may be suppressed in carcinoma [15,16]. This might
indicate that ErbB4 is either unimportant, or actually
antagonizes carcinogenesis. In fact, there is evidence that
ErbB4 expression is associated with positive prognostic
indicators in breast cancer [17,18].
Regulation of ErbB family receptors by peptide
growth factors
EGF family receptors are directly regulated by binding of
diverse polypeptide hormones that each contain a 6-kDa
domain that is homologous to EGF (for review [19•,20•,
21•]). The ligands consist of amphiregulin, betacellulin,
EGF, epiregulin, heparin-binding EGF-like growth factor,
various forms of neuregulin (neuregulin-1, -2, -3, and -4),
and transforming growth factor (TGF)-a. They have differ-
ent abilities to bind to and activate the ErbB family recep-
tors when expressed singly. For example, EGF binds to
the EGF receptor, but not to ErbB2, ErbB3, or ErbB4, and
neuregulin-1 binds to ErbB3 or ErbB4, but not to the EGF
receptor [19•,20•]. EGF family receptors can also be acti-
vated indirectly by agonists that bind serpentine G protein-
coupled receptors [22].
Ligand-dependent regulation of the ErbB family of recep-
tors is expanded through the promiscuous formation of
receptor heterodimers [19•,20•,23]. In cells that express
EGF receptor and ErbB2, any of the EGF agonists will
induce formation of EGF receptor–ErbB2 heterodimers,
as well as EGF receptor–EGF receptor homodimers. This
cross-activation extends to most of the receptor combina-
tions, so that activation of one receptor will generally lead
to some activation of other coexpressed ErbB family
RTKs. Heteromerization can also enhance the affinity of
ligand binding [24•,25]. Heteromerization with other ErbB
family receptors is required for activation of ErbB-3, which
is devoid of intrinsic catalytic activity [26].
ErbB-2 is an orphan receptor, because none of the
soluble ligands bind to ErbB-2 that is expressed indepen-
dently. ErbB-2 is strongly activated through interactions
with other EGF family receptors [27••], however, and
ligand-induced ErbB-2 heteromers are favored over other
heteromers or homomers [28••]. Because ErbB-2 is jointly
expressed with other ErbB family receptors, it can be
thought of as a common subunit that expands the signal-
ing repertoire of the other ErbB family receptors [20•].
Differential regulation of the receptors is important
because each receptor has unique signaling properties
[19•,20•,29]. ErbB-3 is an extreme case, because it has
multiple phosphoinositide 3-kinase-binding sites, and
couples strongly to this signaling molecule [30]. The
response of cells depends on which of the receptors are
activated. Depending on the specific cell context, activa-
tion of these receptors may promote proliferation, motility,
differentiation, or even apoptosis [31–33]. On aggregate,
these interactions may significantly add to, or even alter
the response of cells to ligands [19•]. For example, ErbB2
greatly augments the amplitude and duration of mitogen-
activated protein kinase activation by EGF or neuregulin
[34••]. The differential activation of different receptors and
receptor combinations, as well as the different signaling
abilities of the four ErbB receptors, contributes to the
extraordinary diversity of signals that can be regulated by
the ligands. It also means that the response to a particular
agonist is affected by the spectrum of agonistic hormones
that regulate the system, because there may be inter-
receptor competition for dimerization partners.
Activation of ErbB receptors induces dimerization and
tyrosine phosphorylation. The activation-induced phospho-
peptides recruit docking proteins that themselves convey
the signal further. Although specific ErbB receptors have
been traced to specific responses, less is known about
how these responses correlate with recruitment of spe-
cific pathways and substrates. Once activated, signals are
damped through ligand–receptor dissociation [25],
through phosphorylation (eg by protein kinase C), and by
receptor-mediated endocytosis, which can be followed by
recycling to the cell surface, or proteolytic destruction of
the receptor. The activities of tyrosine phosphatases,Breast Cancer Research    Vol 2 No 3 Stern
including basal phosphatases and those that are recruited
after ligand activation, will further influence the intensity
and duration of signaling.
ErbB family receptors in mammary gland
development
The frequent association of ErbB receptor signaling with
breast cancer reflects the fact that the four ErbB recep-
tors are involved in normal mammary gland development.
The female mammary gland undergoes extensive postnatal
development under the influence of systemic hormones.
Peptide hormones including EGF family ligands, fibroblast
growth factors [35], and insulin-like growth factor-I are
thought to act under control of the systemic hormones as
local mediators of mammary development. All four ErbB
family receptors are expressed in the mammary gland of
adult females, but EGF receptor and ErbB-2 are preferen-
tially expressed in young females [36,37••,38••].
The first postnatal episode of mammary development
occurs at puberty, and leads to elongation and branching
of the mammary ducts to extend throughout the fatty mes-
enchyme. EGF receptor and ErbB-2 are present in stroma
and epithelium, and are tyrosine-phosphorylated, which is
indicative of signaling activity [37••,38••]. The mid-gesta-
tion lethality of disruptions in ErbB-2, ErbB-3, and ErbB-4
has hampered characterization of mammary functions of
these receptors [39•–41•]. The EGF receptor is important
at puberty, because expression of a dominant-negative
EGF receptor impairs ductal morphogenesis [42••]. Sur-
prisingly, reconstitution of stromal/epithelial tissue chimeras
showed that EGF receptor is absolutely required in
mesenchyme, but not in the epithelium [43••]. This does
not rule out redundant functions for EGF receptor in the
epithelium.
The second wave of activation (tyrosine phosphorylation)
of ErbB family receptors occurs in pregnancy [37••,38••].
The activation occurs later than the major period of prolif-
eration. Instead, ligand expression and receptor activation
is most extensive late in pregnancy and after parturition.
Dominant-negative ErbB-2 and ErbB-4 transgenes inter-
fere with lobuloalveolar expansion and milk protein pro-
duction early and late postpartum, respectively, which is
consistent with the ability of neuregulin-activated ErbB-2
to drive mammary differentiation [36,44•,45••,46•].
At least five EGF family ligands are expressed at various
phases of mammary development, where they may
promote proliferation and/or differentiation [37••,38••]. Dis-
ruption of mouse amphiregulin, EGF, and TGF-a genes
identified amphiregulin as a particularly important ligand
for regulation of both ductal outgrowth and lactation. This
is consistent with the high expression of amphiregulin in
the mammary gland [47]. In both the amphiregulin knock-
out mice, and transgenic mice that express the ErbB-4
dominant-negative transgene, the lactational phenotype is
associated with a failure to activate the important intracel-
lular mediator of mammary development Stat5, an SH2
domain-containing transcription factor that regulates pro-
duction of milk proteins [45••,48••].
The functions of ErbB receptors in the mammary gland
may be connected with their roles in carcinogenesis. EGF
agonists are mitogenic in the mammary fat pad of young
females [49], and probably work by concomitant activation
of EGF receptor and ErbB-2. The initial selection for over-
expression of these receptors in cancer precursor cells
might be based on mitogenic coupling of the receptors in
ductal epithelial cells. The elongation of mammary ducts,
which is impaired in amphiregulin-disrupted mice [48••],
involves processes that mirror aspects of tumor invasion,
including changes in intercellular adhesion, and motility.
These changes, even divorced from mitogenic activity of
the receptors, may be important in early stages of tumor
progression. Interestingly, the proliferation and survival of
cells in the mammary gland seems unaffected by disrup-
tion of amphiregulin. Similarly, defects in terminal differen-
tiation and lactation of transgenic mice that express
dominant-negative ErbB-2 and ErbB-4 occur after the
major period of proliferation [44•,45••].
ErbB receptor activation and signaling
heterogeneity
Activation of oncogenes such as RAS in human cancer is
caused by structural mutations that strongly and constitu-
tively activate Ras signaling. The tumor-associated
changes in ErbB family receptors in breast cancer are
generally changes in expression, however, so that normal
modes of regulation are still in operation. Two tumors that
overexpress an ErbB family receptor to the same degree
may be influenced by the receptor in quantitatively or qual-
itatively different ways if other regulatory influences differ.
The fact that overexpressed ErbB receptors can still be
regulated may facilitate drug development. Negative regu-
lators of these receptors that may be worthy therapeutic
targets or models include protein kinase C isoforms, tyro-
sine phosphatases, Cbl (which enhances EGF receptor
turnover; alternative forms of erbB family receptors), and
‘argos’, a physiologic antagonist of the Drosophila EGF
receptor [50•].
In tissue culture, ligand-independent activation of ErbB-2
is sufficient to transform cells even though overexpression
of the EGF receptor has no effect [10]. Overexpression
probably increases receptor phosphorylation and signal-
ing by increasing the rate of inter-receptor collisions. Dif-
ferences between transforming activities of ErbB-2 and
the EGF receptor have been traced to specific portions of
the intracellular domains, indicating that differential signal-
ing qualities are important, and ErbB-2 may also be betterat ligand-independent dimerization [51,52]. Overexpres-
sion of wild-type ErbB-2 in the mammary glands of trans-
genic mice induces metastatic breast cancer [9•,53]. This
animal model revealed that carcinogenesis initiated by
overexpression of ErbB-2 is a multistep process. Tumori-
genicity requires additional structural alterations of ErbB-
2, mutations in other oncogenes, or excessive production
of EGF agonists [54–56]. The structural changes are
small in-frame deletions just outside of the ErbB-2 trans-
membrane domain. These deletions leave unpaired cys-
teine residues that cause constitutive dimerization and
transformation mediated by disulfide bonds. Although
such deletions have not been identified in human tumors,
a splice variant may achieve the same result.
Alternative forms of ErbB family receptors
Variant forms of EGF receptor, ErbB-2, and ErbB-3 can
be produced as a result of differential splicing or proteolytic
processing. Oncogenic forms of the EGF receptor have
been described, albeit seldomly in breast cancer (for
review [57,58]). An alternative spliced form of ErbB-2 has
also been described, in which the exon encoding protein
sequences immediately preceding the transmembrane
domain is skipped. The resulting polypeptide has an
unpaired cysteine and, like the deletion-activated receptor
in the mouse transgenic model, dimerizes constitutively
and transforms cells [13••,59•]. Hence, this spliced variant
mRNA may encode a subpopulation of ErbB-2 molecules
that is primarily responsible for carcinogenesis.
Another set of variant molecules might be less active than
the common receptor forms and dominantly inhibit signal-
ing. Soluble extracellular domains of EGF receptor, ErbB-
2, and ErbB-3 that are encoded by alternative spliced
products may act as sinks or buffers that bind agonists
[60,61]. They can be produced either through direct
coding by spliced variant mRNAs, or through proteolytic
processing of full-length receptors. One such molecule,
‘herstatin’, is encoded by a spliced isoform of ErbB-2, and
disrupts ErbB-2 dimerization and signaling [62•].
Truncated receptors can also be produced through
proteolytic cleavage of full-length molecules. Cleavage of
the extracellular juxtamembrane domain would hypotheti-
cally yield a soluble ectodomain, which may function as an
inhibitor, and concomitantly a truncated anchored recep-
tor that would be constitutively active. Such an activated
form of ErbB-2 is found in a subset of tumors that overex-
press ErbB-2. It is apparently produced through cleavage
by one or more metalloproteinases. This extracellularly
truncated form is activated for signaling, and may be asso-
ciated with lymph node metastasis [63•].
Other sources of signaling heterogeneity
The ligand-activated EGF receptor is downregulated
through receptor-mediated endocytosis. ErbB-2, ErbB-3,
and ErbB-4 show little ligand-dependent endocytosis
compared with the EGF receptor [64•]. Once internalized,
the EGF receptor may be degraded, or, alternatively, recy-
cled to the cell surface. The strong downregulation of the
EGF receptor occurs in part because it preferentially asso-
ciates with the ring-finger protein Cbl, which in turn favors
degradation [65••]. Stability and signaling of the EGF
receptor may be further enhanced by overexpression of
ErbB-2, providing another mechanism through which
ErbB2 overexpression enhances signaling by the EGF
receptor [66].
Autocrine and paracrine regulation of the receptors is
probably of paramount importance in determining the
amount of signal produced by overexpressed ErbB family
receptors. Production of TGF-a, amphiregulin, and
neuregulin have all been described in breast cancer (for
review [21•]). The regulation of ErbB receptors on tumor
cells may change during tumor progression, because the
availability of paracrine ligands may change as tumors
move out from the intraductal environment to invade
locally and distantly.
Another consequence of hormonal stimulation is that it may
qualititatively alter the signaling activity of the receptors.
Different kinase–substrate pairs are juxtaposed in different
receptor dimers, so that signaling by EGF receptor–ErbB2
heterodimers, for example, is different from the sum of
signals emitted by the respective homomers. Differential
positioning of receptors by different ligands may also influ-
ence signaling qualitatively [67•,68,69•].
ErbB receptors are sometimes jointly overexpressed in
breast cancer, suggesting either that they cooperate in
carcinogenesis, or that overexpression of one receptor
upregulates expression of another. In transfection experi-
ments, EGF receptor and ErbB2 synergize in cell transfor-
mation, which is consistent with the former model [24•].
Synergy may result from the ability of ErbB2 in het-
erodimers to stabilize ligand binding and impair EGF
receptor turnover, as discussed above, to expand the
repertoire of pathways activated, or to enhance the dura-
tion of signaling by the two receptors [19•,34••]. In MMTV-
NEU transgenic mouse models, tumors express high
levels of EGF receptor [70] or ErbB-3 [13••]. The latter
apparently results from post-transcriptional upregulation of
ErbB-3 by ErbB-2 [53].
Clinical impact
From the perspective of the clinician, the knowledge that
ErbB family receptors are altered in breast cancer is most
important if it has prognostic value, if it can be used to
make treatment decisions, or if the receptors or ligands
are good therapeutic targets. The most extensive clinical
data are available for ErbB-2. Amplification or overexpres-
sion of ErbB-2 is associated with accelerated relapse and
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mortality [3••] (for review [4•,71•]). Although ErbB-2 status
is not currently in common use for breast cancer treatment
decisions, it may be helpful in borderline situations.
Because Herceptin is most likely to be valuable for
patients with tumors that overexpress ErbB-2, such
patients were selected for earlier clinical trials, and the
drug is approved for use in the USA in this subset of
patients.
Clinical tests that are based on fluorescent in situ
hybridization or immunohistochemistry are typically used
to identify ErbB-2 amplification or overexpression. As dis-
cussed above, signaling heterogeneity could significantly
affect clinical changes associated with receptor overex-
pression and the response to therapeutic antagonists;
whatever role an individual receptor plays in breast
cancer, the clinical variables should correlate best with the
signaling activity of the receptor, rather than with its abun-
dance. The use of phosphorylation-sensitive antibodies
that read out ErbB receptor phosphorylation at specific
sites may be the broadest approach to contending with
these competing forms of regulation, because the phos-
phorylation status of the receptors is a direct measure of
their signaling activity [72,73]. Antibodies that recognize
tyrosine phosphorylated (active) forms of ErbB-2 identify a
subset of breast cancer patients with poor prognosis [74].
Better understanding and quantification of these variables
should greatly augment the clinical utility of ErbB receptor
status (for review [71•]).
The signaling diversity engendered by the different signal-
ing activities of the four receptors means that activation of
specific receptor combinations may be most strongly
linked to tumor aggressiveness, whereas others may be
associated with better prognosis. Thus, the most powerful
clinical predictions may be obtained through quantification
of different receptor activations, and the most powerful
therapeutic strategies may work by targeting specific
subsets of receptors. For example, the synergy of EGF
receptor and ErbB2 in carcinogenesis has suggested the
development of binary therapeutic agents targeting both
receptors [75].
In both tissue culture and clinical studies, overexpression of
ErbB receptors has been associated with resistance to
specific chemotherapeutic agents [76]. Other studies have
suggested that patients with ErbB-2-overexpressing
tumors may benefit from high doses of chemotherapy.
Finally, synergy has been observed between genotoxic
drugs and EGF receptor or ErbB2 antagonists [77–79].
Because of discordances in the research literature, the
extent and mechanisms of these phenomena are controver-
sial, and the reader is referred to reviews of the subject
[4•,71•,80•]. Nonetheless, the evidence clearly demon-
strates that the deployment of ErbB-directed therapies can
have significant impact on the response to other agents.
Changes in ErbB family receptors may also affect
response to hormone therapy with estrogen antagonists.
This may have major practical consequences as therapeu-
tic agents targeting the ErbB receptors are produced,
given the importance of hormone therapy in treating breast
cancer. At least two molecular links have been established
between estrogen receptor and ErbB receptors. Estrogen
suppresses ErbB-2 transcription and expression [81•],
and, conversely, the antagonist tamoxifen has the undesir-
able property of augmenting ErbB2 expression [82•]. ErbB
receptors themselves regulate estrogen-signaling path-
ways, either by directly phosphorylating the estrogen
receptor, or by activating mitogen-activated protein
kinases, which in turn enhance estrogen receptor signal-
ing [83•,84•].
Conclusion
The ErbB family of receptors are outstanding targets for
breast cancer therapies (and diagnosis). Optimal clinical
performance of ErbB-targeted reagents will best be
achieved by harnessing knowledge about the biologic
activities of these receptors in the mammary gland.
Although the fundamentals of ligand regulation of these
receptors have been established, there is still much to be
learned. Work in Drosophila melanogaster suggests that
fine tuning of expression and processing of ligands and
receptors, along with the operation of natural antagonists,
will be important for normal regulation [85•]. The associa-
tion of specific signaling pathways with receptor-specific
functions is not well understood. Finally, understanding
the mechanism of action of Herceptin (for review [86•])
may lead to improved second-generation therapeutics.
Acknowledgements
We thank Dr Michael DiGiovanna for reading the manuscript. This work was
supported by United States Public Health Service grant R01CA45708 from
the National Cancer Institute.
References
Articles of particular interest have been highlighted as:
• of special interest
•• of outstanding interest
1. Cobleigh M, Vogel C, Tripathy D, et al: Efficacy and safety of Her-
•• ceptin (humanized anti-HER2 antibody) as a single agent in 222 
women with HER2 overexpression who relapsed following 
chemotherapy for metastatic breast cancer. In: Proceedings of the 
American Society of Clinical Oncology; Thirty-fourth Annual Meeting. 
Los Angeles, CA: WB Saunders Co, 1998.
The results of Herceptin clinical trials are presented.
2. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin 
•• (humanized anti-HER2 antibody) to first line chemotherapy for 
HER2 overexpressing metastatic breast cancer (HER2 +/MBC) 
markedly increases anticancer activity: a randomized multina-
tional controlled phase III trial. In: American Society of Clinical 
Oncology; Thirty-fourth Annual Meeting. Los Angeles, CA: WB Saun-
ders Co, 1998.
The results of Herceptin clinical trials are preseented.http://breast-cancer-research.com/content/2/3/176
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: corre-
•• lation of relapse and survival with amplification of the HER-2/neu
oncogene. Science 1987, 235:177–182.
This is the first large study to link amplification of ErbB-2 (and not of other
oncogenes) to breast cancer.
4. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role 
• in cancer. Biochem Biophys Acta Rev Cancer 1994, 1198:165–184.
Clinical data and biology are reviewed.
5. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpres-
sion in breast cancer: association with comedo-type ductal carci-
noma in situ and limited prognostic value in stage II breast
cancer. N Engl J Med 1988, 319:1239–1245.
6. Bates N, Hurst H: Transcriptional regulation of Type I receptor
tyrosine kinases in the mammary gland. J Mammary Gland Biol
Neoplasia 1997,  2:153–163.
7. Pollack J, Perou C, Alizadeh A, et al: Genome-wide analysis of DNA
copy-number changes using cDNA microarrays. Nature Genet
1999,  23:41–46.
8. Stein D, Wu J, Fuqua SAW, et al: The SH2 domain protein GRB-7 is
co-amplified, overexpressed and in a tight complex with HER2 in
breast cancer. EMBO J 1994, 13:1331–1340.
9. Guy CT, Webster MA, Schaller M, et al: Expression of the neu pro-
• tooncogene in the mammary epithelium of transgenic mice 
induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:
10578–10582.
A MMTV–Neu transgenic mouse developed metastatic breast cancer.
10. DiFiore P, Pierce J, Kraus M, et al: ErbB-2 is a potent oncogene
when overexpressed in NIH3T3 cells. Science 1987, 237:179–182.
11. Klijn J, Berns P, Schmitz P, Foekens J: The clinical significance of 
• epidermal growth factor receptor (EGF-R) in human breast 
cancer: a review on 5232 patients. Endocr Rev 1992, 13:3–17.
This is a review of clinical literature.
12. Travis A, Pinder S, Robertson J, et al: c-erbB-3 in human breast car-
cinoma: expression and relation to prognosis and established
prognostic indicators. Br J Cancer 1996, 74:229–233.
13. Siegel P, Ryan E, Cardiff R, Muller W: Elevated expression of 
•• activated forms of Neu/ErbB-2 and ErbB-3 are involved in the 
induction of mammary tumors in transgenic mice: implications for 
human breast cancer. EMBO J 1999, 18:49–64.
MMTV–Neu transgenic mice overexpress ErbB-3. Human breast carcino-
mas express an activated exon-skip variant of ErbB-2.
14. Lemoine NR, Barnes DM, Hollywood DP, et al: Expression of the
ERBB3 gene product in breast cancer. Br J Cancer 1992, 66:
1116–1121.
15. Srinivasan R, Poulsom R, Hurst H, Gullick W: Expression of the c-
erbB-4/HER4 protein and mRNA in normal human fetal and adult
tissues and in a survey of nine solid tumour types. J Pathol 1997,
185:236–245.
16. Vogt U, Bielawski K, Schlotter C, et al: Amplification of erbB-4 onco-
gene occurs less frequently than that of erbB-2 in primary human
breast cancer. Gene 1998, 223:375–380.
17. Bacus SS, Chin D, Zelnick CR, Stern DF: Type 1 receptor tyrosine
kinases are differentially phosphorylated in mammary carcinoma
and differentially associated with steroid receptors. Am J Pathol
1996, 148:549–558.
18. Knowlden J, Gee J, Seery L, et al: c-erbB3 and c-erbB4 expression
is a feature of the endocrine responsive phenotype in clinical
breast cancer. Oncogene 1998, 17:1949–1957.
19. Riese DJ II, Stern DF: Specificity within the EGF/ErbB receptor 
• family signaling network. BioEssays 1998, 20:41–48.
This is a review of ligands for ErbB family receptors.
20. Klapper L, Glathe S, Vaisman N, et al: The ErbB-2/HER2 oncopro-
• tein of human carcinomas may function solely as a shared core-
ceptor for multiple stroma-derived growth factors. Proc Natl Acad 
Sci USA 1999, 96:4995–5000.
This review addressed ligand–receptor interactions.
21. Salomon D, Brandt R, Ciardiello F, Normanno N: Epidermal growth 
• factor-related peptides and their receptors in human malignan-
cies. Crit Rev Oncol Hematol 1995, 19:183–232.
This paper reviews EGF ligands and cancer.
22. Prenzel N, Zwick E, Leserer M, Ullrich A: Tyrosine kinase signalling
in breast cancer: epidermal growth factor receptor: convergence
point for signal integration and diversification. Breast Cancer Res
2000, 2:184–190.
23. Riese DJ II, van Raaij TM, Plowman GD, Andrews GC, Stern DF: Cel-
lular response to neuregulins is governed by complex interactions
of the erbB receptor family. Mol Cell Biol 1995, 15:5770–5776.
24. Kokai Y, Meyers JN, Wada T, et al: Synergistic interaction of p185 c-
• neu and the EGF receptor leads to transformation of rodent 
fibroblasts. Cell 1989,  58:287–292.
Synergy between ErbB-2 and EGF receptor is described in this study.
25. Karunagaran D, Tzahar E, Beerli R, et al: ErbB2 is a common auxil-
iary subunit of NDF and EGF receptors: implications for breast
cancer. EMBO J 1996, 15:254–264.
26. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III: Insect
cell-expressed p180erbB3 possesses an impaired tyrosine kinase
activity. Proc Natl Acad Sci USA 1994, 91:8132–8136.
27. Stern DF, Kamps MP: EGF-stimulated tyrosine phosphoryla-
•• tion of p185neu: a potential model for receptor interactions. EMBO 
J 1988, 7:995–1001.
EGF regulates ErbB-2.
28. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of 
•• interreceptor interactions determines signal transduction by neu 
differentiation factor/neuregulin and epidermal growth factor. Mol 
Cell Biol 1996, 16:5276–5287.
This paper describes the ordered hierarchy of heteromerization preferences
for ErbB family receptors.
29. DiFiore PP, Segatto O, Lonardo F, et al: The carboxyl-terminal
domains of erbB-2 and epidermal growth factor receptor exert dif-
ferent regulatory effects on intrinsic receptor tyrosine kinase func-
tion and transforming activity. Mol Cell Biol 1990, 10:2749–2756.
30. Kim H-H, Sierke S, Koland J: Epidermal growth factor-dependent
association of phosphatidylinositol 3-kinase with the erbB3 gene
product. J Biol Chem 1994, 269:24747–24755.
31. Daly J, Jannot C, Beerli R, et al: Neu differentiation factor induces
ErbB2 down-regulation and apoptosis of ErbB2-overexpressing
breast tumor cells. Cancer Res 1997, 57:3804–3811.
32. Bacus SS, Huberman E, Chin D, et al: A ligand for the erbB-2 onco-
gene product (gp30) induces differentiation of human breast
cancer cells. Cell Growth Differ 1992, 3:401–411.
33. Jones FE, Jerry DJ, Guarino BC, Andrews GC, Stern DF: Heregulin
induces  in vivo proliferation and differentiation of mammary
epithelium into secretory lobuloalveoli. Cell Growth Differ 1996,
7:1031–1038.
34. Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody-
•• mediated intracellular retention of erbB-2 impairs neu differentia-
tion factor and epidermal growth factor signaling. Mol Cell Biol
1995, 15:1182–1191.
These elegant subtraction experiments document changes in intracellular
responses to ligands after ErbB-2 is eliminated.
35. Dickson C, Spencer-Dene B, Dillon C, Fantl V: Tyrosine kinase sig-
nalling in breast cancer: fibroblast growth factors and their recep-
tors. Breast Cancer Res 2000, 2:191–196.Breast Cancer Research    Vol 2 No 3 Stern
36. Yang Y, Spitzer E, Meyer D, et al: Sequential requirement of hepato-
cyte growth factor and neuregulin in the morphogenesis and dif-
ferentiation of the mammary gland. J Cell Biol 1995, 131:215–226.
37. Sebastian J, Richards RG, Walker MP, et al: Activation and 
•• function of the epidermal growth factor receptor and erbB-2 
during mammary gland morphogenesis. Cell Growth Differ 1998, 
9:777–785.
In vivo activation of EGFR and ErbB-2 in mammary gland is described.
38. Schroeder JA, Lee DC: Dynamic expression and activation of 
•• ERBB receptors in the developing mouse mammary gland. Cell 
Growth Differ 1998, 9:451–464.
Temporal regulation of ErbB ligands and receptors in mammary gland is
described.
39. Gassmann M, Casagranda F, Orioli D, et al: Aberrant neural and 
• cardiac development in mice lacking the ErbB4 neuregulin recep-
tor. Nature 1995, 378:390–394.
Phenotypes of ErbB4 knockout mice are described.
40. Lee K-F, Simon H, Chen H, et al: Requirement for neuregulin recep-
• tor erbB2 in neural and cardiac development. Nature 1995, 378:
394–398.
Phenotypes of ErbB-2 knockout mice are described.
41. Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, et al: 
• Severe neuropathies in mice with targeted mutation in the ErbB3 
receptor. Nature 1997, 389:725–730.
Phenotypes of ErbB-3 knockout mice are described.
42. Xie W, Paterson A, Chin E, Nabell L, Kudlow J: Targeted 
•• expression of a dominant negative epidermal growth factor recep-
tor in the mammary gland of transgenic mice inhibits pubertal 
mammary duct development. Mol Endocrinol 1997, 1:1766–1781.
A dominant-negative EGF receptor transgene impairs mammary develop-
ment at puberty.
43. Wiesen J, Young P, Werb Z, Cunha G: Signaling through the 
•• stromal epidermal growth factor receptor is necessary for 
mammary ductal development. Development 1999, 126:335–344.
Chimeric mammary glands and tissue grafts demonstrate obligatory require-
ment for EGF receptor in stroma, but not epithelium for mammary gland
development.
44. Jones F, Stern D: Expression of dominant-negative ErbB2 in the 
• mammary gland of transgenic mice reveals a role in lobuloalveo-
lar development and lactation. Oncogene 1999, 18:3481–3490.
Mouse mammary tumor virus-truncated ErbB-2 inhibits lobuloalveolar expan-
sion and lactation in transgenic mouse.
45. Jones FE, Welte T, Fu X-Y, Stern DF: ErbB4 signaling in the 
•• mammary gland is required for lobuloalveolar development and 
Stat5 activation during lactation. J Cell Biol 1999, 147:77–88.
Mouse mammary tumor virus-truncated ErbB-4 inhibits lobuloalveolar expan-
sion during lactation and prevents Stat5 phosphorylation.
46. Niemann C, Brinkmann V, Spitzer E, et al: Reconstitution of 
• mammary gland development in vitro: requirement of c-met and 
c-erbB2 signaling for branching and alveolar morphogenesis. J 
Cell Biol 1998, 143:533–545.
ErbB-2 drives alveolar morphogenesis in mammary gland culture.
47. Kenney NJ, Huang RP, Johnson GR, et al: Detection and location of
amphiregulin and cripto-1 expression in the developing postnatal
mouse mammary gland. Mol Reprod Dev 1995, 41:277–286.
48. Luetteke N, Qiu T, Fenton S, et al: Targeted inactivation of the 
•• EGF and amphiregulin genes reveals distinct roles for EGF recep-
tor ligands in mouse mammary gland development. Development
1999, 126:2739–2750.
Ligand-specific functions of amphiregulin, EGF, and TGF-a in mammary
development are described.
49. Coleman S, Silberstein GB, Daniel CW: Ductal morphogenesis in
the mouse mammary gland: evidence supporting a role for epi-
dermal growth factor. Dev Biol 1988, 127:304–315.
50. Schweitzer R, Howes R, Smith R, Shilo B-Z, Freeman M: Inhibition of 
• Drosophila EGF receptor activation by the secreted protein Argos.
Nature 1995, 376:699–702.
Argos is a natural antagonist of Drosophila melanogaster EGF receptor.
51. DiFiore P, Pierce J, Fleming T, et al: Overexpression of the human
EGF receptor confers and EGF-dependent transformed pheno-
type to HIH 3T3 cells. Cell 1987, 51:1063–1070.
52. Burke CL, Stern DF: Activation of Neu (ErbB-2) mediated by disul-
fide bond-induced dimerization reveals a receptor tyrosine kinase
dimer interface. Mol Cell Biol 1998, 18:5371–5379.
53. Andrechek ER, Muller WJ: Tyrosine kinase signalling in breast
cancer: tyrosine kinase-mediated signal transduction in trans-
genic mouse models of human breast cancer. Breast Cancer
Res 2000,  2:211–216.
54. Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating
mutations in the neu proto-oncogene involved in induction of
mammary tumors. Mol Cell Biol 1994, 14:7068–7077.
55. Li B, Rosen J, McMenamin-Balano J, Muller M, Perkins A: neu/ERBB2
cooperates with p53-172H during mammary tumorigenesis in
transgenic mice. Mol Cell Biol 1997, 17:3155–3163.
56. Muller WJ, Arteaga C, Muthuswamy S, et al: Synergistic Interaction
of the Neu proto-oncogene product and transforming growth
factor  a a in the mammary epithelium of transgenic mice. Mol Cell
Biol 1996, 16:5726–5736.
57. Moscatello D, Holgado-Madruga M, Godwin A, et al: Frequent
expression of a mutant epidermal growth factor receptor in multi-
ple human tumors. Cancer Res 1995, 55:5536–5539.
58. Carter T, Kung HJ: Tissue specific transformation by oncogenic
mutants of epidermal growth factor receptor. Crit Rev Oncogen
1994, 5:389–428.
59. Kwong K, Hung M: A novel splice variant of HER2 with increased 
• transformation activity. Mol Carcinogen 1998, 23:62–68.
A novel transforming ErbB-2 splice variant is described.
60. Petch L, Harris J, Raymond V, et al: A truncated, secreted form of
the epidermal growth factor receptor is encoded by an alterna-
tively spliced transcript in normal rat tissue. Mol Cell Biol 1990,
10:2973–2982.
61. Scott G, Robles R, Park J, et al: A truncated intracellular HER2/neu
receptor produced by alternative RNA processing affects growth
of human carcinoma cells. Mol Cell Biol 1993, 13:2247–2257.
62. Doherty J, Bond C, Jardim A, Adelman J, Clinton G: The HER-2/neu 
• receptor tyrosine kinase gene encodes a secreted autoinhibitor.
Proc Natl Acad Sci USA 1999, 96:10869–10874.
Inhibitory truncated ErbB-2 is produced by alternative splice.
63. Christianson T, Doherty J, Lin Y, et al: NH2-terminally truncated 
• HER-2/neu protein: relationship with shedding of the extracellular 
domain and with prognostic factors in breast cancer. Cancer Res
1998, 58:5123–5129.
ErbB-2 is activated by proteolysis in breast cancer.
64. Baulida J, Kraus M, Alimandi M, Di Fiore P, Carpenter G: All ErbB 
• receptors other than the epidermal growth factor receptor are 
endocytosis impaired. J Biol Chem 1996, 271:5251–5257.
An important regulatory difference within the receptor family is identified.
65. Levkowitz G, Waterman H, Zamir E, et al: c-Cbl/Sli-1 regulates 
•• endocytic sorting and ubiquitination of the epidermal growth 
factor receptor. Genes Dev 1998, 12:3663–3674.
Cbl enforces ubiquitination of EGF receptor.
66. Huang G, Chantry A, Epstein RJ: Overexpression of ErbB2 impairs
ligand-dependent downregulation of epidermal growth factor
receptors via a post-transcriptional mechanism. J Cell Biochem
1999,  74:23–30.http://breast-cancer-research.com/content/2/3/176
67. Crovello C, Lai C, Cantley L, Carraway K III: Differential signaling by 
• the epidermal growth factor-like growth factors neuregulin-1 and 
neuregulin-2. J Biol Chem 1998, 273:26954–26951.
Neuregulin-1 and -2 induce different signals in same cell.
68. Olayioye M, Graus-Porta D, Beerli R, et al: ErbB-1 and ErbB-2
acquire distinct signaling properties dependent upon their dimer-
ization partner. Mol Cell Biol 1998, 18:5042–5051.
69. Muthuswamy S, Gilman M, Brugge J: Controlled dimerization of 
• ErbB receptors provides evidence for differential signaling by 
homo- and heterodimers. Mol Cell Biol 1999, 19:6845–6857.
Signaling is affected by dimerization partner.
70. DiGiovanna M, Lerman M, Coffey R, et al: Active signaling by Neu in
transgenic mice. Oncogene 1998, 17:1877–1884.
71. DiGiovanna MP: Clinical significance of HER-2/neu overexpres-
• sion: part II. In: Principles and Practice of Oncology Updates, vol 13,
no 10. Edited by Rosenberg SA. Cedar Knolls: Lippincott Williams & 
Wilkins, 1999:1–14.
The clinical impact of ErbB-2 overexpression is reviewed.
72. DiGiovanna MP, Stern DF: Activation state specific monoclonal
antibody detects tyrosine phosphorylated p185neu/erbB-2 in a
subset of human breast tumors overexpressing this receptor.
Cancer Res 1995, 55:1946–1955.
73. DiGiovanna MP, Carter D, Flynn SD, Stern DF: Functional assay for
HER-2/neu demonstrates active signaling in a minority of HER-
2/neu overexpressing invasive human breast tumors. Br J Cancer
1996, 74:802–806.
74. Thor A, Liu S, Edgerton S, et al: Activation (tyrosine phosphoryla-
• tion) of ErbB-2 (HER2/neu) as a prognostic factor in node positive 
breast cancer. J Clin Oncol 2000, in press.
Antiphosphorylated ErbB-2 identifies patients with poor prognosis in node-
positive breast cancer.
75. Ye D, Mendelsohn J, Fan Z: Augmentation of a humanized anti-
HER2 mAb 4D5 induced growth inhibition by a human-mouse
chimeric anti-EGF receptor mAb C225. Oncogene 1999,
18:731–738.
76. Pegram M, Finn R, Arzoo K, et al: The effect of HER-2/neu overex-
pression on chemotherapeutic drug sensitivity in human breast
and ovarian cancer cells. Oncogene 1997, 15:537–547.
77. Pietras R, Fendly B, Chazin V, et al: Antibody to HER-2/neu receptor
blocks DNA repair after cisplatin in human breast and ovarian
cancer cells. Oncogene 1993, 9:1829–1838.
78. Aboud-Pirak E, Hurwitz E, Pirak M, et al: Efficacy of antibodies to
epidermal growth factor receptor against KB carcinoma, in vitro
and in nude mice. J Natl Cancer Inst 1988, 80:1605–1611.
79. Arteaga C, Winnier A, Poirier M, et al: p185c-erbB-2 signaling
enhances cisplatin-induced cytotoxicity in human breast carci-
noma cells: association between an oncogenic receptor tyrosine
kinase and drug-induced DNA repair. Cancer Res 1994, 54:
3758–3765.
80. Baselga J, Mendelsohn J: Receptor blockade with monoclonal anti
• bodies as anti-cancer therapy. Pharmacol Ther 1994, 64:127–154.
This paper reviews antibody therapeutics in cancer, including EGF receptor
and ErbB-2.
81. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: Hormonal mod-
• ulation of HER-2/neu protooncogene messenger ribonucleic acid 
and p185 protein expression in human breast cancer cell lines.
Cancer Res 1990, 50:3947–3951.
Estrogen suppresses ErbB-2 expression.
82. Antoniotti S, Maggiora P, Dati C, DeBortoli M: Tamoxifen up-regu-
• lates c-erbB-2 expression in oestrogen-responsive breast cancer 
cells in vitro. Eur J Cancer 1992, 28:318–321.
Tamoxifen augments ErbB-2 expression.
83. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen 
• receptor through phosphorylation by mitogen-activated protein 
kinase. Science 1995,  270:1491–1494.
Interaction of mitogen-activated protein kinases with estrogen receptor is
described.
84. Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase 
• pathway targets estrogen receptor and promotes hormone-
independent growth in human breast cancer cells. Oncogene
1995,  10:2435–2446.
ErbB-2 promotes phosphorylation of estrogen receptor.
85. Perrimon N, Perkins L: There must be 50 ways to rule the signal: 
• the case of the Drosophila EGF receptor. Cell 1997, 89:13–16.
This review surveys regulation of the Drosophila EGF receptor.
86. Sliwkowski M, Lofgren J, Lewis G, et al: Nonclinical studies address-
• ing the mechanism of action of trastuzumab (Herceptin). Semin 
Oncol 1999, 26:60–70.
This is a review of the possible mechanisms of Herceptin action.
Authors’ affiliation: Department of Pathology, Yale University School
of Medicine, New Haven, Connecticut, USA
Correspondence: David F Stern, Department of Pathology, Yale
University School of Medicine, PO Box 208023, New Haven, CT
06520-8023, USA. Tel: +1 203 785 4832; fax: +1 203 785 7467;
e-mail: Stern@biomed.med.yale.edu